Reanalysis of the NCCN PD-L1 companion diagnostic assay study for lung cancer in the context of PD-L1 expression findings in triple-negative breast cancer

David L. Rimm, Gang Han, Janis M. Taube, Eunhee S. Yi, Julia A. Bridge, Douglas B. Flieder, Robert Homer, Anja Roden, Fred R. Hirsch, Ignacio I. Wistuba, Lajos Pusztai

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

The companion diagnostic test for checkpoint inhibitor immune therapy is an immunohistochemical test for PD-L1. The test has been shown to be reproducible for expression in tumor cells, but not in immune cells. Immune cells were used in the IMpassion130 trial which showed PD-L1 expression was associated with a better outcome. Two large studies have been done assessing immune cell PD-L1 expression in lung cancer. Here, we reanalyze one of those studies, to show that, even with an easier scoring method, there is still only poor agreement between assays and pathologist for immune cell PD-L1 expression.

Original languageEnglish (US)
Article number72
JournalBreast Cancer Research
Volume21
Issue number1
DOIs
StatePublished - Jun 13 2019

Fingerprint

Triple Negative Breast Neoplasms
Lung Neoplasms
Routine Diagnostic Tests
Research Design
Neoplasms

Keywords

  • Atezolizumab
  • Immunohistochemistry
  • Non-small cell lung cancer
  • PD-L1
  • Triple-negative breast cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Reanalysis of the NCCN PD-L1 companion diagnostic assay study for lung cancer in the context of PD-L1 expression findings in triple-negative breast cancer. / Rimm, David L.; Han, Gang; Taube, Janis M.; Yi, Eunhee S.; Bridge, Julia A.; Flieder, Douglas B.; Homer, Robert; Roden, Anja; Hirsch, Fred R.; Wistuba, Ignacio I.; Pusztai, Lajos.

In: Breast Cancer Research, Vol. 21, No. 1, 72, 13.06.2019.

Research output: Contribution to journalReview article

Rimm, David L. ; Han, Gang ; Taube, Janis M. ; Yi, Eunhee S. ; Bridge, Julia A. ; Flieder, Douglas B. ; Homer, Robert ; Roden, Anja ; Hirsch, Fred R. ; Wistuba, Ignacio I. ; Pusztai, Lajos. / Reanalysis of the NCCN PD-L1 companion diagnostic assay study for lung cancer in the context of PD-L1 expression findings in triple-negative breast cancer. In: Breast Cancer Research. 2019 ; Vol. 21, No. 1.
@article{0da9b113262b4665827abc63ee7d0a92,
title = "Reanalysis of the NCCN PD-L1 companion diagnostic assay study for lung cancer in the context of PD-L1 expression findings in triple-negative breast cancer",
abstract = "The companion diagnostic test for checkpoint inhibitor immune therapy is an immunohistochemical test for PD-L1. The test has been shown to be reproducible for expression in tumor cells, but not in immune cells. Immune cells were used in the IMpassion130 trial which showed PD-L1 expression was associated with a better outcome. Two large studies have been done assessing immune cell PD-L1 expression in lung cancer. Here, we reanalyze one of those studies, to show that, even with an easier scoring method, there is still only poor agreement between assays and pathologist for immune cell PD-L1 expression.",
keywords = "Atezolizumab, Immunohistochemistry, Non-small cell lung cancer, PD-L1, Triple-negative breast cancer",
author = "Rimm, {David L.} and Gang Han and Taube, {Janis M.} and Yi, {Eunhee S.} and Bridge, {Julia A.} and Flieder, {Douglas B.} and Robert Homer and Anja Roden and Hirsch, {Fred R.} and Wistuba, {Ignacio I.} and Lajos Pusztai",
year = "2019",
month = "6",
day = "13",
doi = "10.1186/s13058-019-1156-6",
language = "English (US)",
volume = "21",
journal = "Breast Cancer Research",
issn = "1465-5411",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Reanalysis of the NCCN PD-L1 companion diagnostic assay study for lung cancer in the context of PD-L1 expression findings in triple-negative breast cancer

AU - Rimm, David L.

AU - Han, Gang

AU - Taube, Janis M.

AU - Yi, Eunhee S.

AU - Bridge, Julia A.

AU - Flieder, Douglas B.

AU - Homer, Robert

AU - Roden, Anja

AU - Hirsch, Fred R.

AU - Wistuba, Ignacio I.

AU - Pusztai, Lajos

PY - 2019/6/13

Y1 - 2019/6/13

N2 - The companion diagnostic test for checkpoint inhibitor immune therapy is an immunohistochemical test for PD-L1. The test has been shown to be reproducible for expression in tumor cells, but not in immune cells. Immune cells were used in the IMpassion130 trial which showed PD-L1 expression was associated with a better outcome. Two large studies have been done assessing immune cell PD-L1 expression in lung cancer. Here, we reanalyze one of those studies, to show that, even with an easier scoring method, there is still only poor agreement between assays and pathologist for immune cell PD-L1 expression.

AB - The companion diagnostic test for checkpoint inhibitor immune therapy is an immunohistochemical test for PD-L1. The test has been shown to be reproducible for expression in tumor cells, but not in immune cells. Immune cells were used in the IMpassion130 trial which showed PD-L1 expression was associated with a better outcome. Two large studies have been done assessing immune cell PD-L1 expression in lung cancer. Here, we reanalyze one of those studies, to show that, even with an easier scoring method, there is still only poor agreement between assays and pathologist for immune cell PD-L1 expression.

KW - Atezolizumab

KW - Immunohistochemistry

KW - Non-small cell lung cancer

KW - PD-L1

KW - Triple-negative breast cancer

UR - http://www.scopus.com/inward/record.url?scp=85067278178&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067278178&partnerID=8YFLogxK

U2 - 10.1186/s13058-019-1156-6

DO - 10.1186/s13058-019-1156-6

M3 - Review article

C2 - 31196152

AN - SCOPUS:85067278178

VL - 21

JO - Breast Cancer Research

JF - Breast Cancer Research

SN - 1465-5411

IS - 1

M1 - 72

ER -